Pfizer’s first loss in two years reported.
OAN’s James Meyers
1:53 PM – Wednesday, November 1, 2023
Pfizer Faces First Quarterly Loss Since 2019
The demand for COVID-19 products has decreased, leading to Pfizer’s first quarterly loss since 2019.
During the third quarter, sales of Pfizer’s coronavirus vaccine dropped by 70% compared to the same period last year. Sales of its COVID-19 treatment Paxlovid also plummeted by 97%.
In October, Pfizer implemented a $3.5 billion cost-cutting program, which reduced its 2023 sales forecast by $9 billion after reclaiming almost 8 million Paxlovid treatment courses from the U.S. government.
Despite the decline, Pfizer plans to keep Paxlovid available to Americans until the end of 2023.
Furthermore, Paxlovid generated $202 million in revenue, a significant drop of 97% from the estimated $613.5 million in sales predicted by experts from FactSet.
In the third quarter, Pfizer reported a net loss of $2.38 billion, or 42 cents per share, compared to a net income of $8.61 billion, or $1.51 per share, during the same period last year.
However, Pfizer remains optimistic, stating that the decline in revenue from COVID-19 products will be partially offset by the growth of new products, acquired products, and indication launches.
Pfizer CEO Albert Bourla expressed his enthusiasm for the strong performance of Pfizer’s non-COVID products in the third quarter of 2023.
Bourla also revealed that the company is expanding its acquisition of cancer-focused biotech company Seagen Inc.
Stay informed! Subscribe here to receive breaking news blasts directly to your inbox for free: https://www.oann.com/alerts
We are entering day three of the trial in Colorado to possibly remove 45th President Donald Trump from the state ballot.
with Mike Davis
with Scott Presler
with Harley Lippman
China’s most popular social media platforms announced that “self-media” accounts with more than 500,000 followers will be required to display real-name information
Intel rose more than 9% on Friday, sparking a surge in chip stocks as the personal computer market rebounds from its quarters-long slump.
Amazon.com surged 7% on Friday as it competes with Microsoft for a larger share of the booming artificial intelligence market.
Malaysia’s communications regulator will issue a warning to social media firms TikTok and Meta for allegedly blocking pro-Palestinian content on their platforms.
rnrn
What are the factors contributing to the decrease in demand for Pfizer’s COVID-19 vaccine and treatment?
Fizer’s quarterly loss highlights the impact of decreased demand for COVID-19 products. The pharmaceutical giant reported its first quarterly loss since 2019, as the sales of its coronavirus vaccine and COVID-19 treatment dropped significantly.
During the third quarter, Pfizer’s sales of the COVID-19 vaccine decreased by 70% compared to the same period last year. This decline in demand can be attributed to various factors, including a decrease in vaccine hesitancy and a shift in focus towards booster shots rather than initial vaccinations. Additionally, Pfizer’s COVID-19 treatment, Paxlovid, witnessed a staggering 97% drop in sales during the same period.
To address this challenging situation, Pfizer implemented a $3.5 billion cost-cutting program in October. This initiative aimed to stabilize the company’s financial position and mitigate the impact of declining COVID-19 product sales. As a result, Pfizer revised its 2023 sales forecast, reducing it by $9 billion.
One of the cost-cutting measures involved Pfizer reclaiming almost 8 million Paxlovid treatment courses from the U.S. government. This decision was a strategic move to optimize inventory levels and align them with the reduced demand. Despite the decline in sales, Pfizer has committed to keeping Paxlovid available to Americans until the end of 2023.
The decline in revenue is evident when examining the financial figures. Paxlovid, which generated $613.5 million in sales last year, only brought in $202 million in revenue during the third quarter. This 97% drop in revenue is significantly lower than the predicted sales estimated by experts from FactSet.
Pfizer reported a net loss of $2.38 billion, equivalent to 42 cents per share, during the third quarter. This stands in stark contrast to the net income of $8.61 billion, or $1.51 per share, recorded during the same period last year. However, Pfizer remains optimistic about its future prospects. The company believes that the decline in revenue from COVID-19 products will be offset, at least partially, by the growth of new products, acquisitions, and indication launches.
Moving forward, Pfizer recognizes the importance of diversifying its product portfolio and focusing on areas beyond COVID-19. The company aims to leverage its research and development capabilities to introduce innovative solutions for various medical conditions. This approach will not only help Pfizer recover from the current setback but also position the company for long-term growth.
In conclusion, Pfizer’s first quarterly loss since 2019 reflects the decreased demand for its COVID-19 products. The drop in vaccine and treatment sales have had a significant impact on the company’s financial performance. However, Pfizer remains hopeful about its future prospects and is taking proactive measures to ensure a path to recovery. By diversifying its product portfolio and focusing on research and development, Pfizer aims to overcome the current challenges and continue contributing to global healthcare.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
